3 Mid-Cap Biotech Stocks To Consider Buying Now

Acadia Pharmaceuticals (NASDAQ: ACAD), Amarin (NASDAQ: AMRN) and Exelixis (NASDAQ: EXEL) check the boxes for what investors should look for in a promising biotech company: compelling drugs, increasing sales, near-term catalysts, and the possibility of being acquired. Like Goldilocks and the Three Bears, these companies are not too big, not too small, but just right.

All three companies market drugs, albeit in different therapeutic areas. Acadia's Nuplazid is approved to treat hallucinations and delusions associated with Parkinson's disease psychosis. Amarin's Vascepa lowers a type of fat called triglycerides, and Exelixis's cabozantinib franchise treats advanced kidney and liver cancers.

Each company has generated meaningful revenues over the past 12 months, ending in the second quarter. Exelixis led the pack with $909.9 million in revenues. Acadia's $264.1 million and Amarin's $292 million are nothing to scoff at either.

Continue reading

Source Fool.com